News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Warns Eli Lilly and Company, Sanofi-Aventis (France), Meda AB on Misleading Promotions
February 4, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. health officials have warned Sanofi Aventis SA, Eli Lilly & Co and Meda AB about misleading promotions for prescription drugs, letters released on Wednesday said.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Regulatory
Eli Lilly and Company
Sanofi
MORE ON THIS TOPIC
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
·
2 min read
·
Tristan Manalac
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Duchenne muscular dystrophy
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
July 1, 2026
·
2 min read
·
Tristan Manalac
